Exogenous Sex Hormones and PONV

Launched by RIVERSIDE UNIVERSITY HEALTH SYSTEM MEDICAL CENTER · Feb 4, 2025

Keywords

ClinConnect Summary

A retrospective cohort study will be performed using the TriNetX database. Cohorts were defined using Common Procedural Terminology and International Classification of Diseases-10 codes. Separate analyses will be performed for hysterectomies, orchiectomies, and augmentation mammoplasties. Patients will be excluded if they had a history of postoperative nausea and vomiting or a history of neoplasm for which the respective procedure would be indicated (e.g., uterine, cervical, testicular, or breast cancer). Transgender patients will be excluded if not on exogenous hormone therapy and cisgende...

Gender

ALL

Eligibility criteria

• Hysterectomy Cohort:
• Inclusion:
• • - Patients who underwent hysterectomies.
• Exclusion:
• • - Patients who had malignant neoplasm of the uterus, ovarian, cervical, endometrium, or adnexa.
• • Transgender Male Group
• Inclusion:
• • administered testosterone within 6 months and 1 day before their hysterectomy
• • have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism.
• • Cisgender Female Group
• Inclusion:
• • - identified as female.
• Exclusion:
• • administered testosterone within 6 months and 1 day before their hysterectomy
• • have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism.
• Orchiectomy Cohort:
• Inclusion:
• • - patients underwent an orchiectomy.
• Exclusion:
• • - history of malignant neoplasm of the testis, malignant neoplasm of the prostate, Fournier gangrene, or vascular disorders of male genital organs
• • Transgender Female Group
• Inclusion:
• • administered estrogen within 6 months and 1 day before their orchiectomy
• • have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism.
• • Cisgender Male Group
• Inclusion:
• • - identified as male.
• Exclusion:
• • administered estrogen within 6 months and 1 day before their orchiectomy
• • have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism.
• Augmentation Mammoplasty:
• Inclusion:
• • - underwent augmentation mammoplasties.
• Exclusion:
• • - Have diagnosis of malignant neoplasm of the breast .
• • Transgender Female Group
• Inclusion:
• • administered estrogen within 6 months and 1 day before their augmentation mammoplasty
• • have one of the following diagnoses: personal history of sex reassignment, gender identity disorder, or transsexualism.
• • Cisgender Female Group
• Inclusion:
• • - Identified as female
• Exclusion:
• • administered estrogen within 6 months and 1 day before their hysterectomy
• • have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism.